A divergence between underlying and final causes of death in selected conditions: an analysis of death registries in Peru

Abstract

BackgroundThe underlying cause of death is used to study country and global mortality trends and profiles. The final cause of death could also inform the ultimately cause of death in individuals with underlying conditions. Whether there is a pattern between the underlying and final cause of death has not been explored using national death registries. We studied what final causes of death were most common among selected underlying causes using national death registries in Peru, 2015.MethodsUnderlying and final causes of death were classified according to their ICD-10 codes. Underlying causes included chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), hypertension (HTN), diabetes, and selected cancers (cervix, breast, stomach, prostate, and lung). Final causes were categorized as: communicable, cardiovascular, and cancers. Descriptive statistics were used.ResultsA total of 77,065 death registries were analyzed; cases had a mean age of 69.4 (SD: 19.3) years at death and were mostly men (53.9%). When the underlying cause was HTN, the most frequent final cause was cardiovascular diseases (82.3%). For all the other underlying causes, the most frequent final cause was communicable diseases: COPD (86.4%), CKD (79.3%), cancer (76.5%), and diabetes (68.3%).ConclusionsIn four selected underlying causes of death there was a divergence with respect to the final cause, suggesting there was a shift from non-communicable to communicable causes. Although efforts should be deployed to prevent underlying non-communicable diseases, potential communicable complications should not be neglected.

Cytoprotective Effects of Dinitrosyl Iron Complexes on Viability of Human Fibroblasts and Cardiomyocytes

“…In addition other toxic effects include myocardial ischemia, systolic or diastolic myocardial dysfunction, cardiomyopathy, chronic heart failure, arterial or pulmonary hypertension, strokes, pericarditis, arrhythmias, thromboembolic disease, and others, extremely adversely affecting the prognosis of these patients (Łacko et al, 2002; Adão et al, 2013; Truong et al, 2014). For several decades, cardiomyopathy caused by chemotherapy for cancer was mainly due to the use of cumulative doses of anthracyclines (doxorubicin, epirubicinum), and trastuzumab, which are the chemotherapeutic agents with the most pronounced cardiac side effects (Łacko et al, 2002; Adão et al, 2013; Truong et al, 2014; Zaorsky et al, 2017; Carrillo-Larco and Bernabe-Ortiz, 2018; Fidale et al, 2018; Ng et al, 2018).…”